Trials Sponsors Conditions Drugs Pricing

Conditions

Breast Adenocarcinoma Breast Cancer Breast Cancer in Situ Breast Cancer Invasive Breast Cancer Stage Breast Cancer Stage IV Breast Neoplasms

Keywords

TransgenderBreast CancerNonbinaryGender DiverseGender-Affirming Hormone Therapy

Outcome Measures

Primary Outcomes (4)

Breast Cancer Diagnosis Method
Describe the method of breast cancer diagnosis (self detected vs screen detected vs healthcare provider detected) and compare to the published data from cisgender women by determining means and standard deviation and comparing rates using the Wilcoxon signed-rank test.
33 years
Breast Cancer Risk Factors
Assess breast cancer risk factors (family history, genetics, etc.), including a prior use of gender-affirming hormone therapy and/or gender-affirming surgery on tumor receptor status and stage at diagnosis using t-test and chi-squared test.
33 years
Breast Cancer Management Strategies
Report breast cancer management strategies (type of breast surgery, receipt of radiation, etc.) through descriptive and comparative staststics with a focus on the use of adjuvant endocrine therapy and gender-affirming hormone therapy for patients with hormone-receptor positive disease using t-test and chi-squared test.

Study Arms (1)

Transgender and Gender-Diverse Persons with Breast Cancer

Patients who had a breast cancer diagnosis (including those with ductal carcinoma in situ (DCIS)), who were age ≥18 years at the time of diagnosis and identify as a gender and/or sex that is different from their sex assigned at birth (e.g., transgender, nonbinary, genderqueer, etc.) between 1/1/1990 - 7/1/2023.

Eligibility Criteria

Age18 Years+

Sexall(Gender-based eligibility)

Gender Eligibility DetailsTransgender and gender-diverse persons (TGD)

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Eligible patients are those who had a breast cancer diagnosis (including those with ductal carcinoma in situ (DCIS), who were age ≥18 years at the time of diagnosis and identify as a gender and/or sex that is different from the sex they were assigned at birth (e.g., transgender, nonbinary, genderqueer, etc.) between 1/1/1990 - 7/1/2023.

You may qualify if:

Sponsors & Collaborators

Medical College of Wisconsin
Otherlead

Study Sites (22)

University of Southern California/Los Angeles (USC/LA County)

Los Angeles, California, 90089, United States

University of California San Francisco (UCSF)

San Francisco, California, 94115, United States

University of Colorado Anschutz Medical Campus (CU Anschutz)

Aurora, Colorado, 80045, United States

MedStar Georgetown University Hospital (MGUH)

Washington D.C., District of Columbia, 20007, United States

Mayo Clinic

Jacksonville, Florida, 32224, United States

Moffitt Cancer Center (MCC)

Tampa, Florida, 33612, United States

Northwestern Medicine

MeSH Terms

Conditions

Breast NeoplasmsBreast Carcinoma In Situ

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue DiseasesCarcinoma in SituCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic Type

Study Officials

Chandler S Cortina
The Medical College of Wisconsin
PRINCIPAL INVESTIGATOR

Enrollment

125 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: RETROSPECTIVE
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Assistant Professor of Surgery

Study Record Dates

First Submitted

January 23, 2024

First Posted

January 31, 2024

Study Start

December 8, 2023

Actual (reported)

Multi-Institutional Transgender & Gender-Diverse Breast Cancer Study

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (4)

Study Arms (1)

Transgender and Gender-Diverse Persons with Breast Cancer

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (22)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (4)

Study Arms (1)

Transgender and Gender-Diverse Persons with Breast Cancer

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (22)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations